Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3-4/2012

01-12-2012

Regulation of the metastatic cell phenotype by sialylated glycans

Authors: Matthew J. Schultz, Amanda F. Swindall, Susan L. Bellis

Published in: Cancer and Metastasis Reviews | Issue 3-4/2012

Login to get access

Abstract

Tumor cells exhibit striking changes in cell surface glycosylation as a consequence of dysregulated glycosyltransferases and glycosidases. In particular, an increase in the expression of certain sialylated glycans is a prominent feature of many transformed cells. Altered sialylation has long been associated with metastatic cell behaviors including invasion and enhanced cell survival; however, there is limited information regarding the molecular details of how distinct sialylated structures or sialylated carrier proteins regulate cell signaling to control responses such as adhesion/migration or resistance to specific apoptotic pathways. The goal of this review is to highlight selected examples of sialylated glycans for which there is some knowledge of molecular mechanisms linking aberrant sialylation to critical processes involved in metastasis.
Literature
1.
Lloyd, K. O., & Old, L. J. (1989). Human monoclonal antibodies to glycolipids and other carbohydrate antigens: dissection of the humoral immune response in cancer patients. Cancer Research, 49, 3445–3451.PubMed
2.
Sell, S. (1990). Cancer-associated carbohydrates identified by monoclonal antibodies. Human Pathology, 21, 1003–1019.PubMed
3.
Varki, A., Kannagi, R., & Toole, B. P. (2009). Glycosylation changes in cancer. In A. Varki, R. D. Cummings, J. D. Esko, H. H. Freeze, P. Stanley, C. R. Bertozzi, G. W. Hart, & M. E. Etzler (Eds.), Essentials of Glycobiology (2nd ed., pp. 580–670). New York: Cold Spring Harbor Laboratory Press.
4.
Hakomori, S. (1989). Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Advances in Cancer Research, 52, 257–331.PubMed
5.
Zhou, D., Levery, S. B., Hsu, F. F., Wang, P. G., Teneberg, S., Almeida, I. C., Li, Y., Xu, H., Wang, L. X., Xia, C., Ibrahim, N. K., & Michael, K. (2011). Immunologic mapping of glycomes: implications for cancer diagnosis and therapy. Frontiers in Bioscience (Scholar Edition), 3, 1520–1532.
6.
Reis, C. A., Osorio, H., Silva, L., Gomes, C., & David, L. (2010). Alterations in glycosylation as biomarkers for cancer detection. Journal of Clinical Pathology, 63, 322–329.PubMed
7.
Drake, P. M., Cho, W., Li, B., Prakobphol, A., Johansen, E., Anderson, N. L., et al. (2010). Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clinical Chemistry, 56, 223–236.PubMed
8.
Fuster, M. M., & Esko, J. D. (2005). The sweet and sour of cancer: glycans as novel therapeutic targets. Nature Reviews Cancer, 5, 526–542.PubMed
9.
Petrescu, A. J., Milac, A. L., Petrescu, S. M., Dwek, R. A., & Wormald, M. R. (2004). Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. Glycobiology, 14, 103–114.PubMed
10.
Sutton, B. J., & Phillips, D. C. (1983). The three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G. Biochemical Society Transactions, 11, 130–132.
11.
Mer, G., Hietter, H., & Lefevre, J. F. (1996). Stabilization of proteins by glycosylation examined by NMR analysis of a fucosylated proteinase inhibitor. Nature Structural Biology, 3, 45–53.PubMed
12.
van Zuylen, C. W., de Beer, T., Leeflang, B. R., Boelens, R., Kaptein, R., Kamerling, J. P., & Vliegenthart, J. F. (1998). Mobilities of the inner three core residues and the Man(alpha 1–6) branch of the glycan at Asn78 of the alpha-subunit of human chorionic gonadotropin are restricted by the protein. Biochemistry, 37, 1933–1940.PubMed
13.
Lotan, R., & Raz, A. (1988). Lectins in cancer cells. Annals of the New York Academy of Sciences, 551, 385–396.PubMed
14.
Drickamer, K., & Taylor, M. E. (1993). Biology of animal lectins. Annual Review of Cell Biology, 9, 237–264.PubMed
15.
16.
Dall’Olio, F., & Chiricolo, M. (2001). Sialyltransferases in cancer. Glycoconjugate Journal, 18, 841–850.PubMed
17.
Varki, N. M., & Varki, A. (2007). Diversity in cell surface sialic acid presentations: implications for biology and disease. Laboratory Investigation, 87, 851–857.PubMed
18.
Schauer, R. (2009). Sialic acids as regulators of molecular and cellular interactions. Current Opinion in Structural Biology, 19, 507–514.PubMed
19.
Cazet, A., Julien, S., Bobowski, M., Burchell, J., & Delannoy, P. (2010). Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Research, 12, 204.PubMed
20.
Cha, S. K., Ortega, B., Kurosu, H., Rosenblatt, K. P., Kuro, O. M., & Huang, C. L. (2008). Removal of sialic acid involving Klotho causes cell–surface retention of TRPV5 channel via binding to galectin-1. Proceedings of the National Academy of Sciences of the United States of America, 105, 9805–9810.PubMed
21.
Isaev, D., Isaeva, E., Shatskih, T., Zhao, Q., Smits, N. C., Shworak, N. W., Khazipov, R., & Holmes, G. L. (2007). Role of extracellular sialic acid in regulation of neuronal and network excitability in the rat hippocampus. Journal of Neuroscience, 27, 11587–11594.PubMed
22.
Rifat, S., Kang, T. J., Mann, D., Zhang, L., Puche, A. C., Stamatos, N. M., Goldblum, S. E., Brossmer, R., & Cross, A. S. (2008). Expression of sialyltransferase activity on intact human neutrophils. Journal of Leukocyte Biology, 84, 1075–1081.PubMed
23.
Jones, M. B., Nasirikenari, M., Lugade, A. A., Thanavala, Y., & Lau, J. T. (2012). Anti-inflammatory IgG production requires a functional P1 promoter in the ST6Gal-1 sialyltransferase gene. Journal of Biological Chemistry, 287, 15365–15370.PubMed
24.
Harduin-Lepers, A., Vallejo-Ruiz, V., Krzewinski-Recchi, M. A., Samyn-Petit, B., Julien, S., & Delannoy, P. (2001). The human sialyltransferase family. Biochimie, 83, 727–737.PubMed
25.
Uemura, T., Shiozaki, K., Yamaguchi, K., Miyazaki, S., Satomi, S., Kato, K., Sakuraba, H., & Miyagi, T. (2009). Contribution of sialidase NEU1 to suppression of metastasis of human colon cancer cells through desialylation of integrin beta4. Oncogene, 28, 1218–1229.PubMed
26.
Gangopadhyay, A., Perera, S. P., & Thomas, P. (1998). Differential expression of alpha2,6-sialyltransferase in colon tumors recognized by a monoclonal antibody. Hybridoma, 17, 117–123.PubMed
27.
Gessner, P., Riedl, S., Quentmaier, A., & Kemmner, W. (1993). Enhanced activity of CMP-neuAc:Gal beta 1-4GlcNAc:alpha 2,6-sialyltransferase in metastasizing human colorectal tumor tissue and serum of tumor patients. Cancer Letters, 75, 143–149.PubMed
28.
Dall’Olio, F., Malagolini, N., di Stefano, G., Minni, F., Marrano, D., & Serafini-Cessi, F. (1989). Increased CMP-NeuAc:Gal beta 1,4GlcNAc-R alpha 2,6 sialyltransferase activity in human colorectal cancer tissues. International Journal of Cancer, 44, 434–439.
29.
Patel, R. Y., & Balaji, P. V. (2006). Identification of linkage-specific sequence motifs in sialyltransferases. Glycobiology, 16, 108–116.PubMed
30.
Danguy, A., Camby, I., & Kiss, R. (2002). Galectins and cancer. Biochimica et Biophysica Acta, 1572, 285–293.PubMed
31.
Nakahara, S., & Raz, A. (2008). Biological modulation by lectins and their ligands in tumor progression and metastasis. Anti-Cancer Agents in Medicinal Chemistry, 8, 22–36.PubMed
32.
Liu, F. T., & Rabinovich, G. A. (2005). Galectins as modulators of tumour progression. Nature Reviews Cancer, 5, 29–41.PubMed
33.
He, J., & Baum, L. G. (2006). Galectin interactions with extracellular matrix and effects on cellular function. Methods in Enzymology, 417, 247–256.PubMed
34.
Ochieng, J., Furtak, V., & Lukyanov, P. (2004). Extracellular functions of galectin-3. Glycoconjugate Journal, 19, 527–535.PubMed
35.
Elola, M. T., Wolfenstein-Todel, C., Troncoso, M. F., Vasta, G. R., & Rabinovich, G. A. (2007). Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cellular and Molecular Life Sciences, 64, 1679–1700.PubMed
36.
Zhuo, Y., & Bellis, S. L. (2010). Emerging role of alpha2,6-sialic acid as a negative regulator of galectin binding and function. Journal of Biological Chemistry, 286, 5935–5941.PubMed
37.
Hirabayashi, J., Hashidate, T., Arata, Y., Nishi, N., Nakamura, T., Hirashima, M., Urashima, T., Oka, T., Futai, M., Muller, W. E., Yagi, F., & Kasai, K. (2002). Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochimica et Biophysica Acta, 1572, 232–254.PubMed
38.
Zhuo, Y., Chammas, R., & Bellis, S. L. (2008). Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis. Journal of Biological Chemistry, 283, 22177–22185.PubMed
39.
Crocker, P. R., Paulson, J. C., & Varki, A. (2007). Siglecs and their roles in the immune system. Nature Reviews Immunology, 7, 255–266.PubMed
40.
Varki, A., & Angata, T. (2006). Siglecs—the major subfamily of I-type lectins. Glycobiology, 16, 1R–27R.PubMed
41.
Jandus, C., Simon, H. U., & von Gunten, S. (2011). Targeting siglecs—a novel pharmacological strategy for immuno- and glycotherapy. Biochemical Pharmacology, 82, 323–332.PubMed
42.
Woodard-Grice, A. V., McBrayer, A. C., Wakefield, J., Zhuo, Y., & Bellis, S. L. (2008). Proteolytic shedding of ST6Gal-I by BACE1 regulates the glycosylation and function of alpha4beta1 integrins. Journal of Biological Chemistry, 283, 26364–26373.PubMed
43.
Pretzlaff, R. K., Xue, V. W., & Rowin, M. E. (2000). Sialidase treatment exposes the beta1-integrin active ligand binding site on HL60 cells and increases binding to fibronectin. Cell Adhesion and Communication, 7, 491–500.PubMed
44.
Amano, M., Galvan, M., He, J., & Baum, L. G. (2003). The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. Journal of Biological Chemistry, 278, 7469–7475.PubMed
45.
Liu, Y. C., Yen, H. Y., Chen, C. Y., Chen, C. H., Cheng, P. F., Juan, Y. H., Khoo, K. H., Yu, C. J., Yang, P. C., Hsu, T. L., & Wong, C. H. (2011). Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 108, 11332–11337.PubMed
46.
Kitazume, S., Imamaki, R., Ogawa, K., Komi, Y., Futakawa, S., Kojima, S., Hashimoto, Y., Marth, J. D., Paulson, J. C., & Taniguchi, N. (2010). Alpha2,6-sialic acid on platelet endothelial cell adhesion molecule (PECAM) regulates its homophilic interactions and downstream antiapoptotic signaling. Journal of Biological Chemistry, 285, 6515–6521.PubMed
47.
Swindall, A. F., & Bellis, S. L. (2011). Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. Journal of Biological Chemistry, 286, 22982–22990.PubMed
48.
Gascoigne, N. R. (2002). T-cell differentiation: MHC class I’s sweet tooth lost on maturity. Current Biology, 12, R99–R101.PubMed
49.
Daniels, M. A., Devine, L., Miller, J. D., Moser, J. M., Lukacher, A. E., Altman, J. D., Kavathas, P., Hogquist, K. A., & Jameson, S. C. (2001). CD8 binding to MHC class I molecules is influenced by T cell maturation and glycosylation. Immunity, 15, 1051–1061.PubMed
50.
Moody, A. M., Chui, D., Reche, P. A., Priatel, J. J., Marth, J. D., & Reinherz, E. L. (2001). Developmentally regulated glycosylation of the CD8alphabeta coreceptor stalk modulates ligand binding. Cell, 107, 501–512.PubMed
51.
Boscher, C., Dennis, J. W., & Nabi, I. R. (2011). Glycosylation, galectins and cellular signaling. Current Opinion in Cell Biology, 23, 383–392.PubMed
52.
Grigorian, A., Torossian, S., & Demetriou, M. (2009). T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunological Reviews, 230, 232–246.PubMed
53.
Garner, O. B., & Baum, L. G. (2008). Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochemical Society Transactions, 36, 1472–1477.PubMed
54.
Lau, K. S., Partridge, E. A., Grigorian, A., Silvescu, C. I., Reinhold, V. N., Demetriou, M., & Dennis, J. W. (2007). Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell, 129, 123–134.PubMed
55.
Lin, S., Kemmner, W., Grigull, S., & Schlag, P. M. (2002). Cell surface alpha 2,6 sialylation affects adhesion of breast carcinoma cells. Experimental Cell Research, 276, 101–110.PubMed
56.
Seales, E. C., Jurado, G. A., Brunson, B. A., Wakefield, J. K., Frost, A. R., & Bellis, S. L. (2005). Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Research, 65, 4645–4652.PubMed
57.
Christie, D. R., Shaikh, F. M., Lucas, J. A., IV, Lucas, J. A., III, & Bellis, S. L. (2008). ST6Gal-1 expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. Journal of Ovarian Research, 1, 3.PubMed
58.
Zhu, Y., Srivatana, U., Ullah, A., Gagneja, H., Berenson, C. S., & Lance, P. (2001). Suppression of a sialyltransferase by antisense DNA reduces invasiveness of human colon cancer cells in vitro. Biochimica et Biophysica Acta, 1536, 148–160.PubMed
59.
Morgenthaler, J., Kemmner, W., & Brossmer, R. (1990). Sialic acid dependent cell adhesion to collagen IV correlates with in vivo tumorigenicity of the human colon carcinoma sublines HCT116, HCT116a and HCT116b. Biochemical and Biophysical Research Communications, 171, 860–866.PubMed
60.
Reddy, B. V., & Kalraiya, R. D. (2006). Sialilated beta1,6 branched N-oligosaccharides modulate adhesion, chemotaxis and motility of melanoma cells: Effect on invasion and spontaneous metastasis properties. Biochimica et Biophysica Acta, 1760, 1393–1402.PubMed
61.
Collard, J. G., Schijven, J. F., Bikker, A., La Riviere, G., Bolscher, J. G., & Roos, E. (1986). Cell surface sialic acid and the invasive and metastatic potential of T-cell hybridomas. Cancer Research, 46, 3521–3527.PubMed
62.
Harvey, B. E., Toth, C. A., Wagner, H. E., Steele, G. D., Jr., & Thomas, P. (1992). Sialyltransferase activity and hepatic tumor growth in a nude mouse model of colorectal cancer metastases. Cancer Research, 52, 1775–1779.PubMed
63.
Bresalier, R. S., Rockwell, R. W., Dahiya, R., Duh, Q. Y., & Kim, Y. S. (1990). Cell surface sialoprotein alterations in metastatic murine colon cancer cell lines selected in an animal model for colon cancer metastasis. Cancer Research, 50, 1299–1307.PubMed
64.
Chiang, C. H., Wang, C. H., Chang, H. C., More, S. V., Li, W. S., & Hung, W. C. (2010). A novel sialyltransferase inhibitor AL10 suppresses invasion and metastasis of lung cancer cells by inhibiting integrin-mediated signaling. Journal of Cellular Physiology, 223, 492–499.PubMed
65.
Chen, J. Y., Tang, Y. A., Huang, S. M., Juan, H. F., Wu, L. W., Sun, Y. C., Wang, S. C., Wu, K. W., Balraj, G., Chang, T. T., Li, W. S., Cheng, H. C., & Wang, Y. C. (2011). A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Research, 71, 473–483.PubMed
66.
Drinnan, N. B., Halliday, J., & Ramsdale, T. (2003). Inhibitors of sialyltransferases: potential roles in tumor growth and metastasis. Mini Reviews in Medicinal Chemistry, 3, 501–517.PubMed
67.
Carcel-Trullols, J., Stanley, J. S., Saha, R., Shaaf, S., Bendre, M. S., Monzavi-Karbassi, B., Suva, L. J., & Kieber-Emmons, T. (2006). Characterization of the glycosylation profile of the human breast cancer cell line, MDA-231, and a bone colonizing variant. International Journal of Oncology, 28, 1173–1183.PubMed
68.
Bos, P. D., Zhang, X. H., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., Minn, A. J., van de Vijver, M. J., Gerald, W. L., Foekens, J. A., & Massague, J. (2009). Genes that mediate breast cancer metastasis to the brain. Nature, 459, 1005–1009.PubMed
69.
Bellis, S. L. (2004). Variant glycosylation: an underappreciated regulatory mechanism for beta1 integrins. Biochimica et Biophysica Acta, 1663, 52–60.PubMed
70.
Gu, J., & Taniguchi, N. (2004). Regulation of integrin functions by N-glycans. Glycoconjugate Journal, 21, 9–15.PubMed
71.
Isaji, T., Kariya, Y., Xu, Q., Fukuda, T., Taniguchi, N., & Gu, J. (2010). Functional roles of the bisecting GlcNAc in integrin-mediated cell adhesion. Methods in Enzymology, 480, 445–459.PubMed
72.
Janik, M. E., Litynska, A., & Vereecken, P. (2010). Cell migration—the role of integrin glycosylation. Biochimica et Biophysica Acta, 1800, 545–555.PubMed
73.
Guo, H. B., Lee, I., Bryan, B. T., & Pierce, M. (2005). Deletion of mouse embryo fibroblast N-acetylglucosaminyltransferase V stimulates alpha5beta1 integrin expression mediated by the protein kinase C signaling pathway. Journal of Biological Chemistry, 280, 8332–8342.PubMed
74.
Seales, E. C., Jurado, G. A., Singhal, A., & Bellis, S. L. (2003). Ras oncogene directs expression of a differentially sialylated, functionally altered beta1 integrin. Oncogene, 22, 7137–7145.PubMed
75.
Shaikh, F. M., Seales, E. C., Clem, W. C., Hennessy, K. M., Zhuo, Y., & Bellis, S. L. (2008). Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms. Experimental Cell Research, 314, 2941–2950.PubMed
76.
Lee, M., Park, J. J., & Lee, Y. S. (2010). Adhesion of ST6Gal I-mediated human colon cancer cells to fibronectin contributes to cell survival by integrin beta1-mediated paxillin and AKT activation. Oncology Reports, 23, 757–761.PubMed
77.
Dalziel, M., Dall’Olio, F., Mungul, A., Piller, V., & Piller, F. (2004). Ras oncogene induces beta-galactoside alpha2,6-sialyltransferase (ST6Gal I) via a RalGEF-mediated signal to its housekeeping promoter. European Journal of Biochemistry, 271, 3623–3634.PubMed
78.
Easton, E. W., Bolscher, J. G., & van den Eijnden, D. H. (1991). Enzymatic amplification involving glycosyltransferases forms the basis for the increased size of asparagine-linked glycans at the surface of NIH 3T3 cells expressing the N-Ras proto-oncogene. Journal of Biological Chemistry, 266, 21674–21680.PubMed
79.
Le Marer, N., Laudet, V., Svensson, E. C., Cazlaris, H., Van Hille, B., Lagrou, C., Stehelin, D., Montreuil, J., Verbert, A., & Delannoy, P. (1992). The c-Ha-Ras oncogene induces increased expression of beta-galactoside alpha-2, 6-sialyltransferase in rat fibroblast (FR3T3) cells. Glycobiology, 2, 49–56.PubMed
80.
Seales, E. C., Shaikh, F. M., Woodard-Grice, A. V., Aggarwal, P., McBrayer, A. C., Hennessy, K. M., & Bellis, S. L. (2005). A protein kinase C/Ras/ERK signaling pathway activates myeloid fibronectin receptors by altering beta1 integrin sialylation. Journal of Biological Chemistry, 280, 37610–37615.PubMed
81.
Semel, A. C., Seales, E. C., Singhal, A., Eklund, E. A., Colley, K. J., & Bellis, S. L. (2002). Hyposialylation of integrins stimulates the activity of myeloid fibronectin receptors. Journal of Biological Chemistry, 277, 32830–32836.PubMed
82.
Pochec, E., Litynska, A., Amoresano, A., & Casbarra, A. (2003). Glycosylation profile of integrin alpha 3 beta 1 changes with melanoma progression. Biochimica et Biophysica Acta, 1643, 113–123.PubMed
83.
Isaji, T., Sato, Y., Fukuda, T., & Gu, J. (2009). N-glycosylation of the I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1. Journal of Biological Chemistry, 284, 12207–12216.PubMed
84.
Akiyama, S. K., Yamada, S. S., & Yamada, K. M. (1989). Analysis of the role of glycosylation of the human fibronectin receptor. Journal of Biological Chemistry, 264, 18011–18018.PubMed
85.
Zheng, M., Fang, H., & Hakomori, S. (1994). Functional role of N-glycosylation in alpha 5 beta 1 integrin receptor. De-N-glycosylation induces dissociation or altered association of alpha 5 and beta 1 subunits and concomitant loss of fibronectin binding activity. Journal of Biological Chemistry, 269, 12325–12331.PubMed
86.
Liu, Y., Pan, D., Bellis, S. L., & Song, Y. (2008). Effect of altered glycosylation on the structure of the I-like domain of beta1 integrin: a molecular dynamics study. Proteins, 73, 989–1000.PubMed
87.
Hedlund, M., Ng, E., Varki, A., & Varki, N. M. (2008). Alpha 2-6-linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Research, 68, 388–394.PubMed
88.
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003). A molecular signature of metastasis in primary solid tumors. Nature Genetics, 33, 49–54.PubMed
89.
Barkan, D., El Touny, L. H., Michalowski, A. M., Smith, J. A., Chu, I., Davis, A. S., Webster, J. D., Hoover, S., Simpson, R. M., Gauldie, J., & Green, J. E. (2010). Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Research, 70, 5706–5716.PubMed
90.
Provenzano, P. P., Eliceiri, K. W., Campbell, J. M., Inman, D. R., White, J. G., & Keely, P. J. (2006). Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Medicine, 4, 38.PubMed
91.
Sidani, M., Wyckoff, J., Xue, C., Segall, J. E., & Condeelis, J. (2006). Probing the microenvironment of mammary tumors using multiphoton microscopy. Journal of Mammary Gland Biology and Neoplasia, 11, 151–163.PubMed
92.
Yoshimura, K., Meckel, K. F., Laird, L. S., Chia, C. Y., Park, J. J., Olino, K. L., Tsunedomi, R., Harada, T., Iizuka, N., Hazama, S., Kato, Y., Keller, J. W., Thompson, J. M., Chang, F., Romer, L. H., Jain, A., Iacobuzio-Donahue, C., Oka, M., Pardoll, D. M., & Schulick, R. D. (2009). Integrin alpha2 mediates selective metastasis to the liver. Cancer Research, 69, 7320–7328.PubMed
93.
Liang, F., Seyrantepe, V., Landry, K., Ahmad, R., Ahmad, A., Stamatos, N. M., & Pshezhetsky, A. V. (2006). Monocyte differentiation up-regulates the expression of the lysosomal sialidase, Neu1, and triggers its targeting to the plasma membrane via major histocompatibility complex class II-positive compartments. Journal of Biological Chemistry, 281, 27526–27538.PubMed
94.
Hinek, A., Pshezhetsky, A. V., von Itzstein, M., & Starcher, B. (2006). Lysosomal sialidase (neuraminidase-1) is targeted to the cell surface in a multiprotein complex that facilitates elastic fiber assembly. Journal of Biological Chemistry, 281, 3698–3710.PubMed
95.
Sawada, M., Moriya, S., Saito, S., Shineha, R., Satomi, S., Yamori, T., Tsuruo, T., Kannagi, R., & Miyagi, T. (2002). Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression. International Journal of Cancer, 97, 180–185.
96.
Miyagi, T., Sato, K., Hata, K., & Taniguchi, S. (1994). Metastatic potential of transformed rat 3Y1 cell lines is inversely correlated with lysosomal-type sialidase activity. FEBS Letters, 349, 255–259.PubMed
97.
Springer, G. F. (1984). T and Tn, general carcinoma autoantigens. Science, 224, 1198–1206.PubMed
98.
Miles, D. W., Happerfield, L. C., Smith, P., Gillibrand, R., Bobrow, L. G., Gregory, W. M., & Rubens, R. D. (1994). Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. British Journal of Cancer, 70, 1272–1275.PubMed
99.
Davidson, B., Gotlieb, W. H., Ben-Baruch, G., Kopolovic, J., Goldberg, I., Nesland, J. M., Berner, A., Bjamer, A., & Bryne, M. (2000). Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases—a clinicopathologic study. Gynecologic Oncology, 77, 35–43.PubMed
100.
Brockhausen, I. (1999). Pathways of O-glycan biosynthesis in cancer cells. Biochimica et Biophysica Acta, 1473, 67–95.PubMed
101.
Taylor-Papadimitriou, J., Burchell, J. M., Plunkett, T., Graham, R., Correa, I., Miles, D., & Smith, M. (2002). MUC1 and the immunobiology of cancer. Journal of Mammary Gland Biology and Neoplasia, 7, 209–221.PubMed
102.
Ikeda, Y., Kuwano, H., Baba, K., Ikebe, M., Matushima, T., Adachi, Y., Mori, M., & Sugimachi, K. (1993). Expression of Sialyl-Tn antigens in normal squamous epithelium, dysplasia, and squamous cell carcinoma in the esophagus. Cancer Research, 53, 1706–1708.PubMed
103.
Itzkowitz, S., Kjeldsen, T., Friera, A., Hakomori, S., Yang, U. S., & Kim, Y. S. (1991). Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology, 100, 1691–1700.PubMed
104.
Itzkowitz, S. H., Yuan, M., Montgomery, C. K., Kjeldsen, T., Takahashi, H. K., Bigbee, W. L., & Kim, Y. S. (1989). Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Research, 49, 197–204.PubMed
105.
Schuessler, M. H., Pintado, S., Welt, S., Real, F. X., Xu, M., Melamed, M. R., Lloyd, K. O., & Oettgen, H. F. (1991). Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer. International Journal of Cancer, 47, 180–187.
106.
Inoue, M., Ogawa, H., Tanizawa, O., Kobayashi, Y., Tsujimoto, M., & Tsujimura, T. (1991). Immunodetection of sialyl-Tn antigen in normal, hyperplastic and cancerous tissues of the uterine endometrium. Virchows Archiv. A, Pathological Anatomy and Histopathology, 418, 157–162.PubMed
107.
Inoue, M., Ton, S. M., Ogawa, H., & Tanizawa, O. (1991). Expression of Tn and sialyl-Tn antigens in tumor tissues of the ovary. American Journal of Clinical Pathology, 96, 711–716.PubMed
108.
Werther, J. L., Rivera-MacMurray, S., Bruckner, H., Tatematsu, M., & Itzkowitz, S. H. (1994). Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. British Journal of Cancer, 69, 613–616.PubMed
109.
Kjeldsen, T., Clausen, H., Hirohashi, S., Ogawa, T., Iijima, H., & Hakomori, S. (1988). Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Research, 48, 2214–2220.PubMed
110.
Zhang, S., Zhang, H. S., Reuter, V. E., Slovin, S. F., Scher, H. I., & Livingston, P. O. (1998). Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clinical Cancer Research, 4, 295–302.PubMed
111.
Gilewski, T. A., Ragupathi, G., Dickler, M., Powell, S., Bhuta, S., Panageas, K., Koganty, R. R., Chin-Eng, J., Hudis, C., Norton, L., Houghton, A. N., & Livingston, P. O. (2007). Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clinical Cancer Research, 13, 2977–2985.PubMed
112.
Julien, S., Picco, G., Sewell, R., Vercoutter-Edouart, A. S., Tarp, M., Miles, D., Clausen, H., Taylor-Papadimitriou, J., & Burchell, J. M. (2009). Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. British Journal of Cancer, 100, 1746–1754.PubMed
113.
Ibrahim, N. K., & Murray, J. L. (2003). Clinical development of the STn-KLH vaccine (Theratope). Clinical Breast Cancer, 3(Suppl 4), S139–S143.PubMed
114.
Kobayashi, H., Terao, T., & Kawashima, Y. (1991). Circulating serum STN antigen as a prognostic marker in epithelial ovarian cancer. Gan to Kagaku Ryoho, 18, 1651–1655.PubMed
115.
Takahashi, I., Maehara, Y., Kusumoto, T., Kohnoe, S., Kakeji, Y., Baba, H., & Sugimachi, K. (1994). Combined evaluation of preoperative serum sialyl-Tn antigen and carcinoembryonic antigen levels is prognostic for gastric cancer patients. British Journal of Cancer, 69, 163–166.PubMed
116.
Kinney, A. Y., Sahin, A., Vernon, S. W., Frankowski, R. F., Annegers, J. F., Hortobagyi, G. N., Buzdar, A. U., Frye, D. K., & Dhingra, K. (1997). The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer, 80, 2240–2249.PubMed
117.
Imai, J., Ghazizadeh, M., Naito, Z., & Asano, G. (2001). Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma. Anticancer Research, 21, 1327–1334.PubMed
118.
Leivonen, M., Nordling, S., Lundin, J., von Boguslawski, K., & Haglund, C. (2001). STn and prognosis in breast cancer. Oncology, 61, 299–305.PubMed
119.
Itzkowitz, S. H., Bloom, E. J., Kokal, W. A., Modin, G., Hakomori, S., & Kim, Y. S. (1990). Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer, 66, 1960–1966.PubMed
120.
Ma, X. C., Terata, N., Kodama, M., Jancic, S., Hosokawa, Y., & Hattori, T. (1993). Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas. European Journal of Cancer, 29A, 1820–1823.PubMed
121.
Therkildsen, M. H., Andersen, L. J., Christensen, M., Hansen, H. S., Schiodt, T., & Dabelsteen, E. (1998). Salivary gland carcinomas: prognostic significance of simple mucin-type carbohydrate antigens. Oral Oncology, 34, 44–51.PubMed
122.
Lundin, M., Nordling, S., Roberts, P. J., Lundin, J., Carpelan-Holmstrom, M., von Boguslawsky, K., & Haglund, C. (1999). Sialyl Tn is a frequently expressed antigen in colorectal cancer: no correlation with patient prognosis. Oncology, 57, 70–76.PubMed
123.
Miles, D., & Papazisis, K. (2003). Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clinical Breast Cancer, 3(Suppl 4), S134–S138.PubMed
124.
Sewell, R., Backstrom, M., Dalziel, M., Gschmeissner, S., Karlsson, H., Noll, T., Gatgens, J., Clausen, H., Hansson, G. C., Burchell, J., & Taylor-Papadimitriou, J. (2006). The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. Journal of Biological Chemistry, 281, 3586–3594.PubMed
125.
Ju, T., Lanneau, G. S., Gautam, T., Wang, Y., Xia, B., Stowell, S. R., Willard, M. T., Wang, W., Xia, J. Y., Zuna, R. E., Laszik, Z., Benbrook, D. M., Hanigan, M. H., & Cummings, R. D. (2008). Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Research, 68, 1636–1646.PubMed
126.
Kobayashi, H., Terao, T., & Kawashima, Y. (1991). Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer. Journal of Clinical Oncology, 9, 983–987.PubMed
127.
Ozaki, H., Matsuzaki, H., Ando, H., Kaji, H., Nakanishi, H., Ikehara, Y., & Narimatsu, H. (2012). Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model. Clinical & Experimental Metastasis, 29, 229–238.
128.
Julien, S., Lagadec, C., Krzewinski-Recchi, M. A., Courtand, G., Le Bourhis, X., & Delannoy, P. (2005). Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration. Breast Cancer Research and Treatment, 90, 77–84.PubMed
129.
Julien, S., Adriaenssens, E., Ottenberg, K., Furlan, A., Courtand, G., Vercoutter-Edouart, A. S., Hanisch, F. G., Delannoy, P., & Le Bourhis, X. (2006). ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology, 16, 54–64.PubMed
130.
Pinho, S., Marcos, N. T., Ferreira, B., Carvalho, A. S., Oliveira, M. J., Santos-Silva, F., Harduin-Lepers, A., & Reis, C. A. (2007). Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Letters, 249, 157–170.PubMed
131.
Julien, S., Krzewinski-Recchi, M. A., Harduin-Lepers, A., Gouyer, V., Huet, G., Le Bourhis, X., & Delannoy, P. (2001). Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconjugate Journal, 18, 883–893.PubMed
132.
Marcos, N. T., Bennett, E. P., Gomes, J., Magalhaes, A., Gomes, C., David, L., Dar, I., Jeanneau, C., DeFrees, S., Krustrup, D., Vogel, L. K., Kure, E. H., Burchell, J., Taylor-Papadimitriou, J., Clausen, H., Mandel, U., & Reis, C. A. (2011). ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Frontiers in Bioscience (Elite Edition), 3, 1443–1455.
133.
Marcos, N. T., Pinho, S., Grandela, C., Cruz, A., Samyn-Petit, B., Harduin-Lepers, A., Almeida, R., Silva, F., Morais, V., Costa, J., Kihlberg, J., Clausen, H., & Reis, C. A. (2004). Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Research, 64, 7050–7057.PubMed
134.
Kono, M., Tsuda, T., Ogata, S., Takashima, S., Liu, H., Hamamoto, T., Itzkowitz, S. H., Nishimura, S., & Tsuji, S. (2000). Redefined substrate specificity of ST6GalNAc II: a second candidate sialyl-Tn synthase. Biochemical and Biophysical Research Communications, 272, 94–97.PubMed
135.
Schneider, F., Kemmner, W., Haensch, W., Franke, G., Gretschel, S., Karsten, U., & Schlag, P. M. (2001). Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-sialyltransferase is related to poor patient survival in human colorectal carcinomas. Cancer Research, 61, 4605–4611.PubMed
136.
Ju, T., Otto, V. I., & Cummings, R. D. (2011). The Tn antigen-structural simplicity and biological complexity. Angewandte Chemie (International Ed. in English), 50, 1770–1791.
137.
Wang, Y., Ju, T., Ding, X., Xia, B., Wang, W., Xia, L., He, M., & Cummings, R. D. (2010). Cosmc is an essential chaperone for correct protein O-glycosylation. Proceedings of the National Academy of Sciences of the United States of America, 107, 9228–9233.PubMed
138.
Hollingsworth, M. A., & Swanson, B. J. (2004). Mucins in cancer: protection and control of the cell surface. Nature Reviews Cancer, 4, 45–60.PubMed
139.
Van Elssen, C. H., Clausen, H., Germeraad, W. T., Bennet, E. P., Menheere, P. P., Bos, G. M., & Vanderlocht, J. (2010). Flow cytometry-based assay to evaluate human serum MUC1-Tn antibodies. Journal of Immunological Methods, 365, 87–94.PubMed
140.
Ligtenberg, M. J., Buijs, F., Vos, H. L., & Hilkens, J. (1992). Suppression of cellular aggregation by high levels of episialin. Cancer Research, 52, 2318–2324.PubMed
141.
Wesseling, J., van der Valk, S. W., & Hilkens, J. (1996). A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane-associated mucin episialin/MUC1. Molecular Biology of the Cell, 7, 565–577.PubMed
142.
Burdick, M. D., Harris, A., Reid, C. J., Iwamura, T., & Hollingsworth, M. A. (1997). Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. Journal of Biological Chemistry, 272, 24198–24202.PubMed
143.
Gunthert, U., Hofmann, M., Rudy, W., Reber, S., Zoller, M., Haussmann, I., Matzku, S., Wenzel, A., Ponta, H., & Herrlich, P. (1991). A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65, 13–24.PubMed
144.
Hofmann, M., Rudy, W., Zoller, M., Tolg, C., Ponta, H., Herrlich, P., & Gunthert, U. (1991). CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Research, 51, 5292–5297.PubMed
145.
Wai, P. Y., & Kuo, P. C. (2004). The role of osteopontin in tumor metastasis. Journal of Surgical Research, 121, 228–241.PubMed
146.
Clement, M., Rocher, J., Loirand, G., & Le Pendu, J. (2004). Expression of sialyl-Tn epitopes on beta1 integrin alters epithelial cell phenotype, proliferation and haptotaxis. Journal of Cell Science, 117, 5059–5069.PubMed
147.
Ogata, S., Maimonis, P. J., & Itzkowitz, S. H. (1992). Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Research, 52, 4741–4746.PubMed
148.
Brinkman-Van der Linden, E. C., & Varki, A. (2000). New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. Journal of Biological Chemistry, 275, 8625–8632.PubMed
149.
Patel, N., Brinkman-Van der Linden, E. C., Altmann, S. W., Gish, K., Balasubramanian, S., Timans, J. C., Peterson, D., Bell, M. P., Bazan, J. F., Varki, A., & Kastelein, R. A. (1999). OB-BP1/Siglec-6. A leptin- and sialic acid-binding protein of the immunoglobulin superfamily. Journal of Biological Chemistry, 274, 22729–22738.PubMed
150.
Barbera-Guillem, E., May, K. F., Jr., Nyhus, J. K., & Nelson, M. B. (1999). Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia, 1, 453–460.PubMed
151.
Barbera-Guillem, E., Nyhus, J. K., Wolford, C. C., Friece, C. R., & Sampsel, J. W. (2002). Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Research, 62, 7042–7049.PubMed
152.
Miles, D., Roche, H., Martin, M., Perren, T. J., Cameron, D. A., Glaspy, J., Dodwell, D., Parker, J., Mayordomo, J., Tres, A., Murray, J. L., & Ibrahim, N. K. (2011). Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. The Oncologist, 16, 1092–1100.PubMed
153.
Geng, Y., Marshall, J. R., & King, M. R. (2011). Glycomechanics of the metastatic cascade: tumor cell-endothelial cell interactions in the circulation. Annals of Biomedical Engineering, 40, 790–805.PubMed
154.
Laubli, H., & Borsig, L. (2010). Selectins promote tumor metastasis. Seminars in Cancer Biology, 20, 169–177.PubMed
155.
Croce, M. V., Isla-Larrain, M., Rabassa, M. E., Demichelis, S., Colussi, A. G., Crespo, M., Lacunza, E., & Segal-Eiras, A. (2007). Lewis x is highly expressed in normal tissues: a comparative immunohistochemical study and literature revision. Pathology and Oncology Research, 13, 130–138.PubMed
156.
Khabaz, M. N., McClure, J., McClure, S., & Stoddart, R. W. (2010). Glycophenotype of prostatic carcinomas. Folia Histochemica et Cytobiologica, 48, 637–645.PubMed
157.
Renkonen, J., Paavonen, T., & Renkonen, R. (1997). Endothelial and epithelial expression of sialyl Lewis(x) and sialyl Lewis(a) in lesions of breast carcinoma. International Journal of Cancer, 74, 296–300.
158.
Croce, M. V., Rabassa, M. E., Pereyra, A., & Segal-Eiras, A. (2008). Differential expression of MUC1 and carbohydrate antigens in primary and secondary head and neck squamous cell carcinoma. Head & Neck, 30, 647–657.
159.
Takada, A., Ohmori, K., Yoneda, T., Tsuyuoka, K., Hasegawa, A., Kiso, M., & Kannagi, R. (1993). Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Research, 53, 354–361.PubMed
160.
Matsuura, N., Narita, T., Mitsuoka, C., Kimura, N., Kannagi, R., Imai, T., Funahashi, H., & Takagi, H. (1997). Increased level of circulating adhesion molecules in the sera of breast cancer patients with distant metastases. Japanese Journal of Clinical Oncology, 27, 135–139.PubMed
161.
Nakagoe, T., Fukushima, K., Itoyanagi, N., Ikuta, Y., Oka, T., Nagayasu, T., Ayabe, H., Hara, S., Ishikawa, H., & Minami, H. (2002). Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. Journal of Cancer Research and Clinical Oncology, 128, 257–264.PubMed
162.
Jeschke, U., Mylonas, I., Shabani, N., Kunert-Keil, C., Schindlbeck, C., Gerber, B., & Friese, K. (2005). Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer Research, 25, 1615–1622.PubMed
163.
Fukuoka, K., Narita, N., & Saijo, N. (1998). Increased expression of sialyl Lewis(x) antigen is associated with distant metastasis in lung cancer patients: immunohistochemical study on bronchofiberscopic biopsy specimens. Lung Cancer, 20, 109–116.PubMed
164.
Tatsumi, M., Watanabe, A., Sawada, H., Yamada, Y., Shino, Y., & Nakano, H. (1998). Immunohistochemical expression of the sialyl Lewis x antigen on gastric cancer cells correlates with the presence of liver metastasis. Clinical & Experimental Metastasis, 16, 743–750.
165.
Baldus, S. E., Zirbes, T. K., Monig, S. P., Engel, S., Monaca, E., Rafiqpoor, K., Hanisch, F. G., Hanski, C., Thiele, J., Pichlmaier, H., & Dienes, H. P. (1998). Histopathological subtypes and prognosis of gastric cancer are correlated with the expression of mucin-associated sialylated antigens: sialosyl-Lewis(a), sialosyl-Lewis(x) and sialosyl-Tn. Tumour Biology, 19, 445–453.PubMed
166.
Nakamori, S., Kameyama, M., Imaoka, S., Furukawa, H., Ishikawa, O., Sasaki, Y., Izumi, Y., & Irimura, T. (1997). Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis. Diseases of the Colon & Rectum, 40, 420–431.
167.
Nakamori, S., Nishihara, S., Ikehara, Y., Nagano, H., Dono, K., Sakon, M., Narimatsu, H., & Monden, M. (1999). Molecular mechanism involved in increased expression of sialyl Lewis antigens in ductal carcinoma of the pancreas. Journal of Experimental & Clinical Cancer Research, 18, 425–432.
168.
Amado, M., Carneiro, F., Seixas, M., Clausen, H., & Sobrinho-Simoes, M. (1998). Dimeric sialyl-Le(x) expression in gastric carcinoma correlates with venous invasion and poor outcome. Gastroenterology, 114, 462–470.PubMed
169.
Grabowski, P., Mann, B., Mansmann, U., Lovin, N., Foss, H. D., Berger, G., Scherubl, H., Riecken, E. O., Buhr, H. J., & Hanski, C. (2000). Expression of SIALYL-Le(x) antigen defined by MAb AM-3 is an independent prognostic marker in colorectal carcinoma patients. International Journal of Cancer, 88, 281–286.
170.
Sozzani, P., Arisio, R., Porpiglia, M., & Benedetto, C. (2008). Is Sialyl Lewis x antigen expression a prognostic factor in patients with breast cancer? International Journal of Surgical Pathology, 16, 365–374.PubMed
171.
Nakayama, T., Watanabe, M., Katsumata, T., Teramoto, T., & Kitajima, M. (1995). Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer, 75, 2051–2056.PubMed
172.
Ugorski, M., & Laskowska, A. (2002). Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochimica Polonica, 49, 303–311.PubMed
173.
Kannagi, R. (2007). Carbohydrate antigen sialyl Lewis a—its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Medical Journal, 30, 189–209.PubMed
174.
Gebauer, G., & Muller-Ruchholtz, W. (1997). Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance. Anticancer Research, 17, 2731–2734.PubMed
175.
Bechtel, B., Wand, A. J., Wroblewski, K., Koprowski, H., & Thurin, J. (1990). Conformational analysis of the tumor-associated carbohydrate antigen 19-9 and its Lea blood group antigen component as related to the specificity of monoclonal antibody CO19-9. Journal of Biological Chemistry, 265, 2028–2037.PubMed
176.
Isozaki, H., Ohyama, T., & Mabuchi, H. (1998). Expression of cell adhesion molecule CD44 and sialyl Lewis A in gastric carcinoma and colorectal carcinoma in association with hepatic metastasis. International Journal of Oncology, 13, 935–942.PubMed
177.
Jorgensen, T., Berner, A., Kaalhus, O., Tveter, K. J., Danielsen, H. E., & Bryne, M. (1995). Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. Cancer Research, 55, 1817–1819.PubMed
178.
Kurebayashi, J., Nomura, T., Hirono, M., Okubo, S., Udagawa, K., Shiiki, S., Ikeda, M., Nakashima, K., Tanaka, K., & Sonoo, H. (2006). Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients. Japanese Journal of Clinical Oncology, 36, 150–153.PubMed
179.
Fujita, T., Murayama, K., Hanamura, T., Okada, T., Ito, T., Harada, M., Komatsu, A., Koyama, H., Kanai, T., Maeno, K., Mochizuki, Y., Hama, Y., Ito, K., Amano, J., & Fujimori, M. (2011). CSLEX (sialyl Lewis X) is a useful tumor marker for monitoring of breast cancer patients. Japanese Journal of Clinical Oncology, 41, 394–399.PubMed
180.
Tsuchida, A., Okajima, T., Furukawa, K., Ando, T., Ishida, H., Yoshida, A., Nakamura, Y., Kannagi, R., & Kiso, M. (2003). Synthesis of disialyl Lewis a (Le(a)) structure in colon cancer cell lines by a sialyltransferase, ST6GalNAc VI, responsible for the synthesis of alpha-series gangliosides. Journal of Biological Chemistry, 278, 22787–22794.PubMed
181.
Kawamura, Y. I., Kawashima, R., Fukunaga, R., Hirai, K., Toyama-Sorimachi, N., Tokuhara, M., Shimizu, T., & Dohi, T. (2005). Introduction of Sd(a) carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis. Cancer Research, 65, 6220–6227.PubMed
182.
Kannagi, R., Sakuma, K., Miyazaki, K., Lim, K. T., Yusa, A., Yin, J., & Izawa, M. (2009). Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: clues in the ongoing search for new tumor markers. Cancer Science, 101, 586–593.PubMed
183.
Julien, S., Ivetic, A., Grigoriadis, A., QiZe, D., Burford, B., Sproviero, D., Picco, G., Gillett, C., Papp, S. L., Schaffer, L., Tutt, A., Taylor-Papadimitriou, J., Pinder, S. E., & Burchell, J. M. (2011). Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Cancer Research, 71, 7683–7693.PubMed
184.
Yamada, N., Chung, Y. S., Takatsuka, S., Arimoto, Y., Sawada, T., Dohi, T., & Sowa, M. (1997). Increased sialyl Lewis A expression and fucosyltransferase activity with acquisition of a high metastatic capacity in a colon cancer cell line. British Journal of Cancer, 76, 582–587.PubMed
185.
Barthel, S. R., Wiese, G. K., Cho, J., Opperman, M. J., Hays, D. L., Siddiqui, J., Pienta, K. J., Furie, B., & Dimitroff, C. J. (2009). Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proceedings of the National Academy of Sciences of the United States of America, 106, 19491–19496.PubMed
186.
Matsuura, N., Narita, T., Hiraiwa, N., Hiraiwa, M., Murai, H., Iwase, T., Funahashi, H., Imai, T., Takagi, H., & Kannagi, R. (1998). Gene expression of fucosyl- and sialyl-transferases which synthesize sialyl Lewisx, the carbohydrate ligands for E-selectin, in human breast cancer. International Journal of Oncology, 12, 1157–1164.PubMed
187.
Majuri, M. L., Niemela, R., Tiisala, S., Renkonen, O., & Renkonen, R. (1995). Expression and function of alpha 2,3-sialyl- and alpha 1,3/1,4-fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. International Journal of Cancer, 63, 551–559.
188.
Matsushita, Y., Cleary, K. R., Ota, D. M., Hoff, S. D., & Irimura, T. (1990). Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases. Laboratory Investigation, 63, 780–791.PubMed
189.
Hanski, C., Drechsler, K., Hanisch, F. G., Sheehan, J., Manske, M., Ogorek, D., Klussmann, E., Hanski, M. L., Blank, M., Xing, P. X., et al. (1993). Altered glycosylation of the MUC-1 protein core contributes to the colon carcinoma-associated increase of mucin-bound sialyl-Lewis(x) expression. Cancer Research, 53, 4082–4088.PubMed
190.
Opolski, A., Laskowska, A., Madej, J., Wietrzyk, J., Klopocki, A., Radzikowski, C., & Ugorski, M. (1998). Metastatic potential of human CX-1 colon adenocarcinoma cells is dependent on the expression of sialosyl Le(a) antigen. Clinical & Experimental Metastasis, 16, 673–681.
191.
Weston, B. W., Hiller, K. M., Mayben, J. P., Manousos, G. A., Bendt, K. M., Liu, R., & Cusack, J. C., Jr. (1999). Expression of human alpha(1,3)fucosyltransferase antisense sequences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells. Cancer Research, 59, 2127–2135.PubMed
192.
Walz, G., Aruffo, A., Kolanus, W., Bevilacqua, M., & Seed, B. (1990). Recognition by ELAM-1 of the sialyl-Lex determinant on myeloid and tumor cells. Science, 250, 1132–1135.PubMed
193.
Phillips, M. L., Nudelman, E., Gaeta, F. C., Perez, M., Singhal, A. K., Hakomori, S., & Paulson, J. C. (1990). ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science, 250, 1130–1132.PubMed
194.
Ben-David, T., Sagi-Assif, O., Meshel, T., Lifshitz, V., Yron, I., & Witz, I. P. (2008). The involvement of the sLe—a selectin ligand in the extravasation of human colorectal carcinoma cells. Immunology Letters, 116, 218–224.PubMed
195.
Takada, A., Ohmori, K., Takahashi, N., Tsuyuoka, K., Yago, A., Zenita, K., Hasegawa, A., & Kannagi, R. (1991). Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A. Biochemical and Biophysical Research Communications, 179, 713–719.PubMed
196.
Hsu, C. C., Lin, T. W., Chang, W. W., Wu, C. Y., Lo, W. H., Wang, P. H., & Tsai, Y. C. (2005). Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids. Gynecologic Oncology, 96, 415–422.PubMed
197.
Shiozaki, K., Yamaguchi, K., Takahashi, K., Moriya, S., & Miyagi, T. (2011). Regulation of sialyl Lewis antigen expression in colon cancer cells by sialidase NEU4. Journal of Biological Chemistry, 286, 21052–21061.PubMed
198.
O, I., Otvos, L., Kieber-Emmons, T., & Blaszczyk-Thurin, M. (2002). Role of SA-Le(a) and E-selectin in metastasis assessed with peptide antagonist. Peptides, 23, 999–1010.PubMed
199.
Biancone, L., Araki, M., Araki, K., Vassalli, P., & Stamenkovic, I. (1996). Redirection of tumor metastasis by expression of E-selectin in vivo. The Journal of Experimental Medicine, 183, 581–587.PubMed
200.
Kohler, S., Ullrich, S., Richter, U., & Schumacher, U. (2010). E-/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. British Journal of Cancer, 102, 602–609.PubMed
201.
Ragupathi, G., Damani, P., Srivastava, G., Srivastava, O., Sucheck, S. J., Ichikawa, Y., & Livingston, P. O. (2009). Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine. Cancer Immunology, Immunotherapy, 58, 1397–1405.PubMed
202.
Ohyama, C., Tsuboi, S., & Fukuda, M. (1999). Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells. EMBO Journal, 18, 1516–1525.PubMed
203.
Fuster, M. M., Brown, J. R., Wang, L., & Esko, J. D. (2003). A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Research, 63, 2775–2781.PubMed
204.
Brown, J. R., Fuster, M. M., Whisenant, T., & Esko, J. D. (2003). Expression patterns of alpha 2,3-sialyltransferases and alpha 1,3-fucosyltransferases determine the mode of sialyl Lewis X inhibition by disaccharide decoys. Journal of Biological Chemistry, 278, 23352–23359.PubMed
205.
Brown, J. R., Fuster, M. M., Li, R., Varki, N., Glass, C. A., & Esko, J. D. (2006). A disaccharide-based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. Clinical Cancer Research, 12, 2894–2901.PubMed
206.
Sawada, R., Sun, S. M., Wu, X., Hong, F., Ragupathi, G., Livingston, P. O., & Scholz, W. W. (2011). Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clinical Cancer Research, 17, 1024–1032.PubMed
207.
Hsu, D. K., Yang, R. Y., & Liu, F. T. (2006). Galectins in apoptosis. Methods in Enzymology, 417, 256–273.PubMed
208.
Fukumori, T., Takenaka, Y., Yoshii, T., Kim, H. R., Hogan, V., Inohara, H., Kagawa, S., & Raz, A. (2003). CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Research, 63, 8302–8311.PubMed
209.
Sanchez-Ruderisch, H., Detjen, K. M., Welzel, M., Andre, S., Fischer, C., Gabius, H. J., & Rosewicz, S. (2011). Galectin-1 sensitizes carcinoma cells to anoikis via the fibronectin receptor alpha5beta1-integrin. Cell Death and Differentiation, 18, 806–816.PubMed
210.
Lajoie, P., Partridge, E. A., Guay, G., Goetz, J. G., Pawling, J., Lagana, A., Joshi, B., Dennis, J. W., & Nabi, I. R. (2007). Plasma membrane domain organization regulates EGFR signaling in tumor cells. The Journal of Cell Biology, 179, 341–356.PubMed
211.
Earl, L. A., Bi, S., & Baum, L. G. (2010). N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. Journal of Biological Chemistry, 285, 2232–2244.PubMed
212.
Nangia-Makker, P., Nakahara, S., Hogan, V., & Raz, A. (2007). Galectin-3 in apoptosis, a novel therapeutic target. Journal of Bioenergetics and Biomembranes, 39, 79–84.PubMed
213.
Lee, M., Lee, H. J., Bae, S., & Lee, Y. S. (2008). Protein sialylation by sialyltransferase involves radiation resistance. Molecular Cancer Research, 6, 1316–1325.PubMed
214.
Liu, Z., Swindall, A. F., Kesterson, R. A., Schoeb, T. R., Bullard, D. C., & Bellis, S. L. (2011). ST6Gal-I regulates macrophage apoptosis via alpha2-6 sialylation of the TNFR1 death receptor. Journal of Biological Chemistry, 286, 39654–39662.PubMed
215.
Moller, P., Koretz, K., Leithauser, F., Bruderlein, S., Henne, C., Quentmeier, A., & Krammer, P. H. (1994). Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. International Journal of Cancer, 57, 371–377.
216.
Lebel, M., Bertrand, R., & Mes-Masson, A. M. (1996). Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice. Oncogene, 12, 1127–1135.PubMed
217.
Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., & Galle, P. R. (1996). Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion? Nature Medicine, 2, 1361–1366.PubMed
218.
Peter, M. E., Budd, R. C., Desbarats, J., Hedrick, S. M., Hueber, A. O., Newell, M. K., Owen, L. B., Pope, R. M., Tschopp, J., Wajant, H., Wallach, D., Wiltrout, R. H., Zornig, M., & Lynch, D. H. (2007). The CD95 receptor: apoptosis revisited. Cell, 129, 447–450.PubMed
219.
Ametller, E., Garcia-Recio, S., Costamagna, D., Mayordomo, C., Fernandez-Nogueira, P., Carbo, N., Pastor-Arroyo, E. M., Gascon, P., & Almendro, V. (2010). Tumor promoting effects of CD95 signaling in chemoresistant cells. Molecular Cancer, 9, 161.PubMed
220.
Lai, Y. J., Lin, V. T., Zheng, Y., Benveniste, E. N., & Lin, F. T. (2010). The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration. Molecular and Cellular Biology, 30, 5582–5596.PubMed
221.
Nijkamp, M. W., Hoogwater, F. J., Steller, E. J., Westendorp, B. F., van der Meulen, T. A., Leenders, M. W., Borel Rinkes, I. H., & Kranenburg, O. (2010). CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. Journal of Hepatology, 53, 1069–1077.PubMed
222.
Yuan, K., Jing, G., Chen, J., Liu, H., Zhang, K., Li, Y., Wu, H., McDonald, J. M., & Chen, Y. (2011). Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK). Journal of Biological Chemistry, 286, 24776–24784.PubMed
223.
Chen, L., Park, S. M., Tumanov, A. V., Hau, A., Sawada, K., Feig, C., Turner, J. R., Fu, Y. X., Romero, I. L., Lengyel, E., & Peter, M. E. (2009). CD95 promotes tumour growth. Nature, 465, 492–496.
224.
Baldwin, R. L., Tran, H., & Karlan, B. Y. (1999). Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis. Gynecologic Oncology, 74, 265–271.PubMed
225.
Landowski, T. H., Gleason-Guzman, M. C., & Dalton, W. S. (1997). Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood, 89, 1854–1861.PubMed
226.
Natoli, G., Ianni, A., Costanzo, A., De Petrillo, G., Ilari, I., Chirillo, P., Balsano, C., & Levrero, M. (1995). Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene, 11, 1157–1164.PubMed
227.
O’Connell, J., Bennett, M. W., O’Sullivan, G. C., Roche, D., Kelly, J., Collins, J. K., & Shanahan, F. (1998). Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. The Journal of Pathology, 186, 240–246.PubMed
228.
Keppler, O. T., Peter, M. E., Hinderlich, S., Moldenhauer, G., Stehling, P., Schmitz, I., Schwartz-Albiez, R., Reutter, W., & Pawlita, M. (1999). Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotropic virus. Glycobiology, 9, 557–569.PubMed
229.
Peter, M. E., Hellbardt, S., Schwartz-Albiez, R., Westendorp, M. O., Walczak, H., Moldenhauer, G., Grell, M., & Krammer, P. H. (1995). Cell surface sialylation plays a role in modulating sensitivity towards APO-1-mediated apoptotic cell death. Cell Death and Differentiation, 2, 163–171.PubMed
230.
Suzuki, O., Nozawa, Y., & Abe, M. (2003). Sialic acids linked to glycoconjugates of Fas regulate the caspase-9-dependent and mitochondria-mediated pathway of Fas-induced apoptosis in Jurkat T cell lymphoma. International Journal of Oncology, 23, 769–774.PubMed
231.
Lee, K. H., Feig, C., Tchikov, V., Schickel, R., Hallas, C., Schutze, S., Peter, M. E., & Chan, A. C. (2006). The role of receptor internalization in CD95 signaling. EMBO Journal, 25, 1009–1023.PubMed
232.
Buhe, V., Loisel, S., Pers, J. O., Le Ster, K., Berthou, C., & Youinou, P. (2010). Updating the physiology, exploration and disease relevance of complement factor H. International Journal of Immunopathology and Pharmacology, 23, 397–404.PubMed
233.
Meesmann, H. M., Fehr, E. M., Kierschke, S., Herrmann, M., Bilyy, R., Heyder, P., Blank, N., Krienke, S., Lorenz, H. M., & Schiller, M. (2010). Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes. Journal of Cell Science, 123, 3347–3356.PubMed
Metadata
Title
Regulation of the metastatic cell phenotype by sialylated glycans
Authors
Matthew J. Schultz
Amanda F. Swindall
Susan L. Bellis
Publication date
01-12-2012
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3-4/2012
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9359-7

Other articles of this Issue 3-4/2012

Cancer and Metastasis Reviews 3-4/2012 Go to the issue

NON-THEMATIC REVIEW

Ovarian cancer molecular pathology

OriginalPaper

TGF-β signalling and its role in cancer progression and metastasis

NON-THEMATIC REVIEW

Transcription factor PROX1: its role in development and cancer

OriginalPaper

Driving transcriptional regulators in melanoma metastasis

OriginalPaper

Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment

OriginalPaper

Metastasis suppression by BRMS1 associated with SIN3 chromatin remodeling complexes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits